Lipocine Inc. balance sheet LPCN

Annual Quarterly

As of Sep 30, 2026, Lipocine Inc. had total assets of $23.2 million and total liabilities of $2.0 million. Total assets were up 44.3% from a year earlier. Stockholders' equity was $21.2 million. Cash and investments were $21.5 million. The current ratio, current assets divided by current liabilities, was 11.36.

USD in millions, except ratios and per-share amounts. The percent under a figure is the change from the year before.

FY 2026
Sep 30, 2026
FY 2025
Dec 31, 2025
FY 2024
Dec 31, 2024
FY 2023
Dec 31, 2023
FY 2022
Dec 31, 2022
FY 2021
Dec 31, 2021
FY 2020
Dec 31, 2020
FY 2019
Dec 31, 2019
FY 2018
Dec 31, 2018
FY 2017
Dec 31, 2017
FY 2016
Dec 31, 2016
Assets
Cash
3
-33.5%
5
-16.1%
6
+30.1%
5
+51.6%
3
+6.7%
3
-84.6%
19
+97.5%
10
+20.4%
8
+151.6%
3
-42.3%
6
-72.2%
Short-term investments
19
+68.0%
10
-37.0%
15
-10.6%
17
-41.2%
29
-29.5%
42
+9159.6%
0
-89.6%
4
-39.5%
7
-60.7%
18
-14.2%
21
-12.7%
Long-term investments
—
—
—
—
—
2
—
—
—
—
0
-100.0%
Cash and investments
21
+41.8%
15
-31.0%
22
-1.8%
22
-36.2%
33
-27.1%
47
+137.1%
20
+39.8%
14
-7.8%
15
-29.0%
21
-20.0%
27
-40.1%
Total current assets
23
+45.1%
17
-24.4%
22
-2.4%
23
-33.0%
34
-26.4%
46
+83.1%
25
+29.0%
20
-5.7%
21
-17.5%
25
-7.3%
27
-39.4%
Property and equipment, net
0
-49.5%
0
-36.8%
0
+42.2%
0
-11.8%
0
+1724.8%
0
+102.9%
—
0
-81.3%
0
-74.7%
0
-27.4%
0
+36.6%
Total assets
23
+44.3%
17
-24.5%
23
-2.1%
23
-38.7%
38
-28.5%
52
+107.0%
25
+29.0%
20
-5.7%
21
-17.7%
25
-7.4%
27
-39.7%
Liabilities and equity
Accounts payable
1
-36.8%
1
+257.7%
0
-80.5%
1
+132.5%
1
-53.4%
1
-19.3%
2
+35.1%
1
+76.1%
1
+12.2%
1
+143.2%
0
-51.5%
Total current liabilities
2
+5.4%
3
+67.1%
2
-42.5%
3
+56.8%
2
-70.1%
6
-14.7%
7
+32.6%
5
+10.5%
4
-29.2%
6
+378.5%
1
-60.9%
Total liabilities
2
+5.4%
3
+67.1%
2
-42.5%
3
+37.9%
2
-72.4%
7
-31.0%
10
-25.1%
13
+17.1%
11
+80.0%
6
+378.5%
1
-60.9%
Stockholders' equity
21
+49.6%
14
-31.1%
21
+3.1%
20
-42.8%
36
-21.8%
46
+197.0%
15
+144.0%
6
-33.3%
9
-50.3%
19
-27.0%
26
-38.0%
Debt
Long-term debt
—
—
—
—
—
2
-66.7%
5
-25.0%
7
-33.3%
10
—
—
Total debt
—
—
—
—
—
2
-66.7%
5
-25.0%
7
-33.3%
10
—
—
Net cash
—
—
—
—
—
45
+206.6%
15
+98.2%
7
+41.0%
5
—
—
Ratios
Current ratio
11.36x
6.68x
14.75x
8.69x
20.34x
8.26x
3.85x
3.95x
4.63x
3.97x
20.52x
Debt to equity
—
—
—
—
—
0.04x
0.33x
1.06x
1.06x
—
—
Debt to EBITDA
—
—
—
—
—
0.53x
—
—
—
—
—
Return on equity
-44.09%
-66.50%
0.04%
-80.28%
-30.19%
-1.39%
-136.65%
-206.87%
-123.60%
-110.55%
-72.92%
Return on assets
-40.22%
-56.61%
0.04%
-71.09%
-28.66%
-1.21%
-82.69%
-66.17%
-55.92%
-82.85%
-69.38%
Book value per share
2.57
2.35
3.93
3.83
6.81
0.52
0.22
0.17
0.43
0.89
1.41
How these figures are calculated

Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions, except ratios and per-share amounts. Cash and investments adds short-term and long-term marketable securities to cash. Debt due within a year is the borrowings that are not already in long-term debt. Total debt is those borrowings plus lease liabilities. Net cash is cash and investments minus total debt. Return on equity and return on assets divide the trailing twelve months of net income by the balance on that date. Debt to EBITDA uses the trailing twelve months of EBITDA. The first column is the latest balance sheet when it is newer than the latest fiscal year. More on our methodology.

Company profile

Industry
Pharmaceutical Preparations (SIC 2834)
Listed as
LPCN (Nasdaq)
Fiscal year ends
December 31
Incorporated in
DE
Headquarters
Salt Lake City, United States
SEC filer status
Non-accelerated filer, Smaller reporting company
SEC CIK
1535955
Former names
MARATHON BAR CORP (until Jul 9, 2013)

Other Pharmaceutical Preparations companies

All 570 Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.